NEW YORK (GenomeWeb) – Quest Diagnostics has confirmed that it will stop offering Natera's non-invasive prenatal test after Sequenom recently inked a deal with Quest to offer its MaterniT21 Plus test.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.
At Nature, John Wilbanks and Eric Topol call for openness in health data.
Law.com predicts that genomic and genetic testing will become common in toxic tort cases.
A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.